MedTrace Logo

Efficacy and Safety of Probiotics in Neonatal Hyperbilirubinemia

NCT03266913 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2017-08-30

No results posted yet for this study

Summary

Neonatal Jaundice occurs in 60% of term infants and 80% of premature infants. Although it is transient, it is associated with high rate of readmission of patients in the first week of infancy. Neonatal jaundice can cause neurological complications and kernicterus. Considering the fact that there have been a lot of studies on probiotic role in management of necrotizing enterocolitis (NEC) and few studies on their role in neonatal jaundice, we carried out this study to determine the efficacy and safety of probiotics in neonatal hyperbilirubinemia in infants hospitalized in children hospital in Bandar Abbas.

Conditions

  • Hyperbilirubinemia, Neonatal

Interventions

DRUG

Probiotic

Probiotics drop

Sponsors & Collaborators

  • Hormozgan University of Medical Sciences

    lead OTHER

Principal Investigators

  • Rakhshaneh Goodarzi, M.D · Hormozgan University of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
2 Days
Max Age
28 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-01
Primary Completion
2017-10-01
Completion
2017-11-01

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03266913 on ClinicalTrials.gov